Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2011; 17(12): 1631-1641
Published online Mar 28, 2011. doi: 10.3748/wjg.v17.i12.1631
Published online Mar 28, 2011. doi: 10.3748/wjg.v17.i12.1631
Table 1 Cholangiocarcinoma samples tested for serum anti Opisthorchis viverrini antibody
| No. | Code | Anti-OV titer (OD)1 | OV positive |
| 1 | M009 | 0.804 | + |
| 2 | M012 | 0.303 | + |
| 3 | M030 | 0.820 | + |
| 4 | M043 | 0.182 | - |
| 5 | M055 | 0.185 | - |
| 6 | M068 | 0.356 | + |
| 7 | M071 | 0.257 | + |
| 8 | M097 | 0.188 | - |
| 9 | M101 | 0.235 | + |
| 10 | M111 | 0.088 | - |
| 11 | M114 | 0.285 | + |
| 12 | M117 | 0.345 | + |
| 13 | M119 | 0.168 | - |
| 14 | M132 | 0.095 | - |
| 15 | M137 | 0.330 | + |
| 16 | M139 | 0.239 | + |
| 17 | M142 | 0.344 | + |
| 18 | M148 | 0.305 | + |
| 19 | M152 | 0.108 | - |
| 20 | M155 | 0.642 | + |
| 21 | M157 | 0.482 | + |
| 22 | M208 | 0.952 | + |
| 23 | M214 | 0.188 | - |
| 24 | M229 | 0.165 | - |
| 25 | M240 | 0.669 | + |
| 26 | M265 | 0.314 | + |
| 27 | M279 | 0.502 | + |
| 28 | N004 | 0.218 | + |
| 29 | N021 | 0.232 | + |
Table 2 Primer sequences of genomic and reverse transcription polymerase chain reaction, and polymerase chain reaction fragment sizes
| Primer name | Forward (5→3) | Reverse (5→3) | Product size (bp) |
| Genomic-PCR | |||
| TFF1 | CAGGGATCTGCCTGCATC | ATCGATCTCTTTTAATTTTTAGGCC | 219 |
| TFF2 | GAAGAATCTCCCGAACCAGG | GTCACACTTCAAAAACTAGAGG | 123 |
| TFF3 | CAGGCACTGTTCATCTCAGC | TATTCGTTAAGACATCAGGCTCC | 129 |
| β-actin | TCACCCACACTGTGCCCATCTACGA | CAGCGGAACCGCTCATTGCCAATGG | 375 |
| RT-PCR | |||
| TFF1 | CCCGTGAAAGACAGAATT | GATCCCTGCAGAAGTGTCT | 169 |
| TFF2 | CTCCTGGCAGCGCTCCTCGTC | GATGCCCGGGTAGCCACAGTTTCT | 223 |
| TFF3 | AACCGGGGCTGCTGCTTTG | GAGGTGCCTCAGAAGGTGC | 92 |
| RPLP0 | CTTCCCACTTGCTGAAAAG | CCAAATCCCATATCCTCGT | 168 |
Table 3 Associations of trefoil factor protein expression in cholangiocarcinoma
| TFF protein expression | n | TFF2 | TFF3 | ||||
| Negative | Positive | P-value | Negative | Positive | P-value | ||
| TFF1 | 110 | ||||||
| Negative | 54 | 42 | 12 | NS | 34 | 20 | 0.014 |
| Positive | 56 | 40 | 16 | 22 | 34 | ||
| TFF2 | 110 | ||||||
| Negative | 82 | 44 | 38 | NS | |||
| Positive | 28 | 12 | 16 | ||||
Table 4 Relative copy number of trefoil factor genes in cholangiocarcinoma
| No. | TFF1 | TFF2 | TFF3 |
| 1 | 2.031 | 1.691 | 2.311 |
| 2 | 1.431 | 1.371 | 1.721 |
| 3 | 1.551 | 1.371 | 2.341 |
| 4 | 2.001 | 2.191 | 2.911 |
| 5 | 1.461 | 1.731 | 1.841 |
| 6 | 1.791 | 1.781 | 3.211 |
| 7 | 1.821 | 2.741 | 3.671 |
| 8 | 1.441 | 0.96 | 1.381 |
| 9 | 1.551 | 0.98 | 1.781 |
| 10 | 1.551 | 0.99 | 1.561 |
| 11 | 1.681 | 1.30 | 2.361 |
| 12 | 1.681 | 1.10 | 1.401 |
| 13 | 1.971 | 0.85 | 2.171 |
| 14 | 1.611 | 1.33 | 2.321 |
| 15 | 1.581 | 1.00 | 1.581 |
| 16 | 1.621 | 1.22 | 2.891 |
| 17 | 1.491 | 1.17 | 1.351 |
| 18 | 1.521 | 0.97 | 2.251 |
| 19 | 1.621 | 1.21 | 1.851 |
| 20 | 1.14 | 1.10 | 1.551 |
| 21 | 1.17 | 0.98 | 1.661 |
| 22 | 0.83 | 0.92 | 1.571 |
| 23 | 1.14 | 1.03 | 1.481 |
| 24 | 0.98 | 1.14 | 1.411 |
| 25 | 1.06 | 1.15 | 1.651 |
| 26 | 1.06 | 1.33 | 2.131 |
| 27 | 1.32 | 0.91 | 1.421 |
| 28 | 1.20 | 1.01 | 1.571 |
| 29 | 1.27 | 1.631 | 1.851 |
| 30 | 1.32 | 1.891 | 1.581 |
| 31 | 1.29 | 2.681 | 2.161 |
| 32 | 1.28 | 1.381 | 1.871 |
| 33 | 0.88 | 1.481 | 1.631 |
| 34 | 1.491 | 1.421 | 1.24 |
| 35 | 1.381 | 0.71 | 0.99 |
| 36 | 1.771 | 1.03 | 1.12 |
| 37 | 1.381 | 0.92 | 1.29 |
| 38 | 1.511 | 1.17 | 0.94 |
| 39 | 1.521 | 1.02 | 1.23 |
| 40 | 1.461 | 1.12 | 1.34 |
| 41 | 1.421 | 0.97 | 1.34 |
| 42 | 1.371 | 0.73 | 0.79 |
| 43 | 0.84 | 0.472 | 0.58 |
| 44 | 0.63 | 0.372 | 0.88 |
| 45 | 0.68 | 0.532 | 0.86 |
| 46 | 0.63 | 0.512 | 0.83 |
| 47 | 0.86 | 0.382 | 0.55 |
| 48 | 0.76 | 0.422 | 0.462 |
| 49 | 0.92 | 0.68 | 0.452 |
| 50 | 0.82 | 0.85 | 0.512 |
| 51 | 1.07 | 0.79 | 0.97 |
| 52 | 1.15 | 0.59 | 1.11 |
| 53 | 0.95 | 0.84 | 1.02 |
| 54 | 0.84 | 0.79 | 0.68 |
| 55 | 0.74 | 0.77 | 1.26 |
| 56 | 0.77 | 1.03 | 0.83 |
| 57 | 1.13 | 1.31 | 1.26 |
| 58 | 1.13 | 1.03 | 1.20 |
| 59 | 1.00 | 0.88 | 0.89 |
| 60 | 1.17 | 0.70 | 1.15 |
| 61 | 0.94 | 0.91 | 1.19 |
| 62 | 0.76 | 0.72 | 0.63 |
| 63 | 1.15 | 1.04 | 1.15 |
| 64 | 1.25 | 0.95 | 0.87 |
| 65 | 1.01 | 0.77 | 0.90 |
| 66 | 1.11 | 1.27 | 1.03 |
| 67 | 0.85 | 0.62 | 0.54 |
| 68 | 1.10 | 0.96 | 1.23 |
| 69 | 1.06 | 0.92 | 0.84 |
| 70 | 1.05 | 0.88 | 0.80 |
| 71 | 1.12 | 1.09 | 1.10 |
| 72 | 1.33 | 0.87 | 1.22 |
| 73 | 0.87 | 1.01 | 0.71 |
| 74 | 0.75 | 0.88 | 0.76 |
| 75 | 1.04 | 0.74 | 1.14 |
| 76 | 1.10 | 0.67 | 0.93 |
| 77 | 1.06 | 0.98 | 1.14 |
| 78 | 1.10 | 0.97 | 1.30 |
| 79 | 1.22 | 0.87 | 1.21 |
| 80 | 1.16 | 0.95 | 1.32 |
| 81 | 1.13 | 1.07 | 1.32 |
| 82 | 1.10 | 0.88 | 1.24 |
| 83 | 0.92 | 1.05 | 1.31 |
| 84 | 1.14 | 0.97 | 1.09 |
| 85 | 1.01 | 0.98 | 1.14 |
| 86 | 1.13 | 1.07 | 1.26 |
| 87 | 0.91 | 0.59 | 1.23 |
| 88 | 0.97 | 0.69 | 1.16 |
| 89 | 0.91 | 0.78 | 0.91 |
| 90 | 1.06 | 0.71 | 1.06 |
| 91 | 1.15 | 0.69 | 0.88 |
| 92 | 0.96 | 0.58 | 0.57 |
| 93 | 1.03 | 1.00 | 1.30 |
| 94 | 1.20 | 0.93 | 1.06 |
| 95 | 1.25 | 0.76 | 0.77 |
| 96 | 1.28 | 1.21 | 1.24 |
| 97 | 1.28 | 1.15 | 0.94 |
| 98 | 1.10 | 0.82 | 0.99 |
| 99 | 1.28 | 0.73 | 0.71 |
| 100 | 0.87 | 0.59 | 0.91 |
| 101 | 1.05 | 0.78 | 1.28 |
| 102 | 1.00 | 0.70 | 0.99 |
| 103 | 0.66 | 0.61 | 0.61 |
| 104 | 0.89 | 0.74 | 0.80 |
| 105 | 0.88 | 0.57 | 0.60 |
| 106 | 0.82 | 0.56 | 0.58 |
| 107 | 1.04 | 1.05 | 1.04 |
| 108 | 0.90 | 0.98 | 0.88 |
| 109 | 0.65 | 0.65 | 0.64 |
| 110 | 1.18 | 1.21 | 1.20 |
- Citation: Kosriwong K, Menheniott TR, Giraud AS, Jearanaikoon P, Sripa B, Limpaiboon T. Trefoil factors: Tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma. World J Gastroenterol 2011; 17(12): 1631-1641
- URL: https://www.wjgnet.com/1007-9327/full/v17/i12/1631.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i12.1631
